- Applied Therapeutics, Inc. reports financial results for Q2 2025, highlighting progress in CMT-SORD treatment with govorestat. A meeting with the FDA is scheduled in Q3 2025 to discuss a potential NDA submission. The company launched a sponsored Sorbitol Assay for CMT-SORD patients and entered an out-licensing agreement for AT-001 with Biossil, Inc.
- Results from the INSPIRE Phase 2/3 trial of govorestat for CMT-SORD showed slowed disease progression at 24 months. New data on govorestat for PMM2-CDG will be presented at the 2025 ASHG Annual Meeting. The review of the govorestat development program for Classic Galactosemia is progressing as planned.
- Applied Therapeutics announced key leadership promotions and financial results for Q2 2025. Cash and cash equivalents totaled $30.4 million, with a decrease in net loss compared to the same period in 2024. The company continues to focus on developing novel drug candidates for rare diseases like CMT-SORD, Classic Galactosemia, and PMM2-CDG.
Read more at GlobeNewswire: Applied Therapeutics Reports Second Quarter 2025 Financial